Once the most promising hit compounds have been identified as leads through the efforts of hit to lead, it will enter the stage of lead optimization and preclinical development of early drug development, which are the key processes for finalizing drug candidates entering clinical trials. Lead optimization aims to improve the properties of lead compounds including stability, potency, efficacy, exposure, safety, etc. Lead optimization involves a sophisticated iterative stage in which the bioactivity and drug activity of the lead series are extensively optimized through various screening filters, and development candidates are ultimately determined for preclinical development. Preclinical development, also known as IND-enabling studies, involves testing development candidates in various in vitro and in vivo assays to examine their safety pharmacology and toxicology profile.
With established in vitro/in vivo approaches and our advanced zebrafish screening platform, Creative Biostructure can start from the identified potential lead compounds to study stability, bioavailability, toxicity, efficacy, and other pharmacokinetic parameters to improve their target specificity and potency. Our lead optimization and preclinical development solutions can provide you with better quality leads that have a high probability of success in clinical development.